Interview with Michael Pehl, Managing Director, Celgene Germany
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Address: Sanofi-Aventis Deutschland GmbH
Industriepark Höchst, K703
65926 Frankfurt
,Germany
Tel: 0180 / 2 222010
Web: http://www.sanofi.de/l/de/de/index.jsp
The Sanofi-Aventis Deutschland GmbH is the German subsidiary of one of the world’s leading pharmaceutical companies. The Group employs approximately 100,000 employees worldwide and maintains strong market positions in the regions of North America, Europe and Asia. Its core business is the original innovative prescription drugs for the treatment (drugs) and prevention (vaccines) of serious, widespread diseases. The R & D expenditures by sanofi-aventis in 2008 amounted to 4.6 billion euros, of which, the Sanofi-Aventis Deutschland GmbH about 600 million euros worn. But not only the high use of resources is decisive – the research from sanofi-aventis is one of the most productive and successful worldwide. Currently, sanofi-aventis 65 novel drugs and vaccines in development. Of these 27 projects are in advanced clinical stage III or in the admission process. The focus is on seven core therapeutic areas: diabetes / metabolism, cardiovascular, thrombosis, central nervous system, internal medicine, oncology and vaccines. In Germany, one of sanofi-aventis with sales (including export) of 4.0 billion euros of the leading providers of innovative medicines.
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
See our Cookie Privacy Policy Here
